StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$41.31−0.19 (-0.46%)

Close on Oct 19, 2026Market cap $48.13BP/E 68.9Yield –

Teva Pharmaceutical Industries GAAP Gross Profit by Quarter

GAAP Gross Profit (Per Non-GAAP Reconciliation Table) ($M)

Teva Pharmaceutical Industries GAAP Gross Profit: $2,440M in Q3 2026, up 5.9% from a year earlier. That is the highest of the 15 quarters on record here.

Latest, Q3 2026
2,440
Period ended Sep 30, 2026
Change on a year earlier
+5.9%
2,304 in Q3 2025
History
15 quarters
Since Q4 2021
Sources
11
Documents cited below

Where the Q3 2026 figure comes from

“|| Gross profit | $ | 2,440 | 2,304 | $ | 6,565 | 6,282”

Source: Form 8-K Earnings Release (0001171843-26-007054) ↗

Reported in SEC Form 10-K / Form 10-Q / Form 8-K Earnings Releases.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Teva Pharmaceutical Industries GAAP Gross Profit ($M), quarterly Q4 2021–Q3 2026 [Data set]. Compiled from Teva Pharmaceutical Industries SEC filings and investor materials. https://stockdatahq.com/stocks/teva/kpis/ng-gaap-gp

See every metric in the Teva Pharmaceutical Industries KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?